Citations

Clear

1792 citation(s) found for "Stephanie".

Sexuality and sexual health in older adults—recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024)
Luria, Mijal , Ros, Carlos Teodósio Da , Srini, Vasan Satya , Da Ros, Carlos , Faubion, Stephanie, Park, Kwangsung , Gewirtz‐Meydan, Ateret , Arbanas, Goran , Ho, Christopher C.K. , Srini, Vasan Satya , Faubion, Stephanie S.

Mayo Clinic

Sexual Medicine Reviews | November 25, 2025 | Volume: 14 | Issue: 1 | Pages: No page available

10.1093/sxmrev/qeaf069 | PMID 41370314 Get It

Abstract Introduction This is the first International Consultation on Sexual Medicine (ICSM) position paper on sexual health in older adults. Physical, cognitive, and psychosocial factors create a unique set of challenges related to sexuality in older adults. Objectives This study explores the impact of the physiological aspects of aging, state of health, psychological, relationship-related, and sociocultural factors, on sexual health in older adults. The goal of this review is to provide recommendations for the comprehensive evaluation and treatment of this population. Methods A narrative review was conducted under the auspices of the ICSM, as part of its ongoing efforts to develop expert, evidence-based guidance in the field of sexual health. A multidisciplinary panel of international experts composed of specialists in urology, gynecology, psychiatry, sexual medicine, social work, and sex therapy was convened. A comprehensive literature review was conducted based on a search of psychological sources (PsycInfo), medical databases (PubMed, Medline), and Google Scholar. All retrieved articles were reviewed and critically assessed. Recommendations were then formulated using a modified Delphi method. Results Although there is extensive literature on the prevalence and risk of sexual challenges of adults over the age of 65, there is limited evidence regarding the quality of treatment modalities. In particular, there is scant data on women in this age group. This population faces specific and multifactorial challenges, which point to the need for a comprehensive approach to their care. Conclusion Any approach to sexual health in older adults needs to take all the factors that affect sexual health into account, while endorsing the full spectrum of sexual expression in a non-judgmental way. Individuals in a relationship should be offered a couple-centered approach. Special attention is needed for individuals in cognitive decline. Healthcare providers must be aware of ageist biases, which may prevent them from providing appropriate care.
Psychosocial stress in women with functional hypothalamic amenorrhea and potential implications for cardiovascular disease risk
Klejc, Kamelia, Safwan, Nancy , Stouffer, Kelly, Berga, Sarah L. , Andrade, Maria D. Hurtado, Shufelt, Chrisandra , Shufelt, Chrisandra L , Andrade, Maria D. Hurtado, Faubion, Stephanie S. , Mehta, Puja K.

Mayo Clinic

Stress | November 24, 2025 | Volume: 28 | Issue: 1 | Pages: No page available

10.1080/10253890.2025.2589533 | PMID 41276920 Get It

Multidimensional Single-Cell Transcriptomic Profiling of Uterine Leiomyosarcomas Reveals Distinct Tumor States with Inferred Therapeutic Vulnerabilities
Korah, Maria, Agolia, James Paul , Reddy, Biren , Flojo, Renceh A. B., Wang, Lilin , Bethi, Rishik, Bobst, Wesley, Liang, Brooke, Yip, Kaylin A., Tabora, Angela D, Hsu, Chia-Hsin, Reveron‐Thornton, Rosyli F. , Guo, Chuner, Delitto, Andrea E., Xie, Peter Y., Tomasso, Antonio, Daniel, Sara K. , Litkouhi, Babak , Moding, Everett J. , Poultsides, George A. , Norton, Jeffrey A. , Charville, Gregory W. , Ganjoo, Kristen N. , Lee, Byrne , Longaker, Michael T., Gonçalves, Amanda Costa , Bethi, Rishik, Liang, Brooke, Yip, Kaylin A., Hsu, Chia-Hsin, Guo, Chuner, Gruener, Robert F. , Xie, Peter Y., Tomasso, Antonio, Sun, Beatrice J. , Dorigo, Oliver , Bui, Nam Q. , Pan, Minggui , Kalbasi, Anusha K. , Kirane, Amanda , Newman, Aaron M. , Foster, Deshka S. , Huang, R. Stephanie , Delitto, Daniel

Mayo Clinic

No container title available | November 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.11.17.688894 Get It

Abstract Uterine leiomyosarcoma (ULMS) is an orphan disease that frequently recurs and metastasizes, with patients undergoing multiple lines of chemotherapy due to lack of effective therapeutic targets. To address this gap, we used single-cell RNA sequencing and spatial transcriptomic analysis to comprehensively profile ULMS. We uncovered multiple states of tumor cells, including tumor cells with mesenchyme-like features, ischemic tumor cells defined by a MYC program, inflammatory tumor cells with active interferon signaling, and stem cell-like hormone receptor-positive cells. The inferred spatial correlates of these tumor cell states demonstrated unique localization patterns. By correlating these signatures to bulk RNA sequencing data, we demonstrate the relevance of these findings to clinical outcomes. Finally, using the single-cell integration and drug response prediction algorithm (scIDUC), we propose drug predictions that may target specific tumor states. Our findings suggest new avenues for further exploration of individualized and multifaceted therapeutic strategies to treat ULMS.
Associations of lifestyle factors with amyloid pathology in persons without dementia
Oomens, Julie Elisabeth , Vos, Stephanie J. B. , Maserejian, Nancy N., Didic, Mira , Engelborghs, Sebastiaan , Fladby, Tormod, Fröhlich, Lutz, Gill, Kiran Dip, Grimmer, Timo, Itoh, Yoshiaki , Landau, Susan, Lleó, Alberto, Meyer, Philipp T. , Pardini, Matteo , Rami, Lorena , Reiman, Eric M. , Rinne, Juha O. , Sánchez‐Juan, Pascual, Scarmeas, Nikolaos , Villeneuve, Sylvia , Waldemar, Gunhild , Alcolea, Daniel, Altomare, Daniele , Baldeiras, Inês , Blennow, Kaj , Cerman, Jiří , Chipi, Elena , Day, Gregory S. , Förster, Stefan , Frings, Lars , Guedj, Éric , Habeck, Christian , Hausner, Lucrezia , Jiménez‐Bonilla, J., Juaristi, Arantxa, Kern, Silke , Kirsebom, Bjørn‐Eivind , Legdeur, Nienke , Xiong, Chengjie , Maier, W., Marquié, Marta, Minatani, Shinobu, Prabhakar, Sudesh, Ramakers, Inez H.G.B. , Rodríguez‐Rodríguez, Eloy , Ruiz, Agustín, Rüther, E., Sakhardande, Jayant, Selnes, Per, Spiru, Luiza , Vermunt, Lisa , Wallin, Åsa K., Zettergren, Anna , (ADNI), for the Alzheimer's Disease Neuroimaging Initiative, group, A4 Study, (DIAN), Dominantly Inherited Alzheimer Network, (KBASE), Japan Alzheimer's Disease Neuroimaging Initiative (J-ADNI), Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease, Ossenkoppele, Rik, Verhey, Frans RJ, Visser, Pieter Jelle, Jansen, Willemijn J, Marquié, Marta , Selnes, Per , Day, Gregory S , Xiong, Chengjie , Oomens, Julie E , Boada, Merçé , Fladby, Tormod , Flier, Wiesje M. van der , Frisoni, Giovanni B. , Fröhlich, Lutz, Grimmer, Timo , Hort, Jakub , Iwatsubo, Takeshi , Klimkowicz‐Mrowiec, Aleksandra , Lee, Dong Young , Lleó, Alberto , Martínez‐Lage, Pablo , Mendonça, Alexandre de , Parchi, Piero , Parnetti, Lucilla , Popp, Julius , Rodrigue, Karen M. , Santana, Isabel , Scheltens, Philip , Skoog, Ingmar , Sperling, Reisa Anne , Stern, Yaakov , Wiltfang, Jens , Zetterberg, Henrik , Alcolea, Daniel , Allegri, Ricardo , Bateman, Randall J. , Baiardi, Simone , Braber, Anouk den , Buchem, Mark A. van , Byun, Min Soo , Chen, Kewei , Drzezga, Alexander E. , Ekblad, Laura L. , Fortea, Juan , Freund‐Levi, Yvonne , Handels, Ron , Hellwig, Sabine , Kandimalla, Ramesh , Kornhuber, Johannes , Morbelli, Silvia , Mroczko, Barbara , Ntanasi, Eva , Oliveira, Catarina Resende , Orellana, Adelina , Peters, Oliver , Ruiz, Agustı́n , Silva, Dina , Soininen, Hilkka S. , Takeda, Akitoshi , Teunissen, Charlotte E. , Tijms, Betty M. , Wiels, Wietse A. , Yannakoulia, Mary , Yi, Dahyun , (ADNI), for the Alzheimer's Disease Neuroimaging Initiative, group, A4 Study, (DIAN), Dominantly Inherited Alzheimer Network, (KBASE), Japan Alzheimer's Disease Neuroimaging Initiative (J-ADNI), Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease, Ossenkoppele, Rik, Verhey, Frans R.J. , Visser, Pieter Jelle , Jansen, Willemijn J.

Mayo Clinic

Journal of Alzheimer’s Disease | November 14, 2025 | Volume: 108 | Issue: 3 | Pages: 1043-1059

10.1177/13872877251379083 | PMID 41234025 Get It

Background The association between lifestyle factors and Alzheimer's disease (AD) pathophysiology remains incompletely understood. Objective The aim of this study was to assess the association of alcohol consumption, smoking behavior, sleep quality and physical, cognitive, and social activity with cerebral amyloid pathology. Methods For this cross-sectional study, we selected participants from the Amyloid Biomarker Study data pooling initiative. We used generalized estimating equations to assess associations of dichotomized lifestyle measures with amyloid pathology. Results We included 9171 participants with normal cognition (NC) and 2555 participants with mild cognitive impairment (MCI) from the Amyloid Biomarker Study. Of participants with NC, 58% were women, 34% were APOE ε4 carrier, and 27% had amyloid pathology. Of participants with MCI, 48% were women, 47% were APOE ε4 carrier, and 57% had amyloid pathology. In NC, cognitively active participants were less likely to have amyloid pathology (OR = 0.77, 95%CI 0.66–0.89, p < 0.001). In MCI, participants who had ever smoked or had sleep problems were less likely to have amyloid pathology (OR = 0.85, 95%CI 0.73–0.99, p = 0.029; OR = 0.62, 95%CI 0.45–0.86, p = 0.004). Conclusions In NC, cognitive activity was associated with a lower frequency of amyloid pathology. In MCI, favorable lifestyle behaviors were not associated with a lower frequency of amyloid pathology. The results of the current study contribute to the broader evidence base on lifestyle and AD by further characterizing the role of lifestyle behaviors in AD pathology across different clinical stages.
SLC44A1::PRKCA fusion-positive glioneuronal tumor without histological and epigenetic features of papillary glioneuronal tumor
Huynh, Vy , Zhang, Dan , Hardcastle, Jayson, Smoley, Stephanie A., Isaacson, Matthew, Gandham, Mallika , Dasari, Surendra , Abdullaev, Zied , Aldape, Kenneth , Quezado, Martha , Cimino, Patrick J. , Raghunathan, Aditya , Smoley, Stephanie , Lachance, Daniel, Cimino, Patrick J , Raghunathan, Aditya , Isaacson, Matthew, Pratt, Drew , Lachance, Daniel Honore , Ida, Cristiane M.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | November 13, 2025 | Volume: 85 | Issue: 7 | Pages: 797-800

10.1093/jnen/nlaf133 | PMID 41230946 Get It

Recommendations for Studying In Situ Extracellular Vesicles From Solid Tissue
Crescitelli, Rossella , Hendrix, An , Hill, Andrew F. , Ikezu, Tsuneya , Levy, Efrat , Puig, Berta , Paolini, Lucia , Vella, Laura J. , Hill, Andrew F , Ikezu, Tsuneya , Puig, Berta , Paolini, Lucia , Huang, Yiyao , Hurwitz, Stephanie N.

Mayo Clinic

Journal of Extracellular Vesicles | November 12, 2025 | Volume: 14 | Issue: 11 | Pages: No page available

10.1002/jev2.70185 | PMID 41220186 Get It

ABSTRACT Solid tissue‐derived extracellular vesicles (ST‐EVs) are extracellular vesicles (EVs) separated directly from solid tissues of both vertebrates and invertebrates. ST‐EVs provide a physiologically relevant snapshot of tissue‐specific molecular dynamics and can be enriched directly in situ, from tissues in their natural state, preserving the native characteristics of ST‐EVs. However, their enrichment presents unique technical challenges compared to EVs derived from biofluids or cell culture media. The need for transparent reporting in ST‐EV research is crucial to enhance the reproducibility, comparability, and reliability of research findings. The Solid Tissue Task Force, part of the Scientific Reproducibility Subcommittee of International Society for Extracellular Vesicles, aims to recommend reporting parameters and identify outstanding questions related to the pre‐analytical and analytical handling of solid tissues, as well as ST‐EV separation and characterization. These steps are essential for advancing the understanding of the biological roles of ST‐EVs and their potential clinical applications.
QOL-12. Patient and caregiver priorities in neuro-oncology care
Webb, Lauren M. , Reiland, Julie, Valerius, Allison , Barath, Abhijeet S. , Galloway, Taylor , Reiland, Julie, Baddeley, Elin , Sivell, Stephanie , Sener, Uğur

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v382-v382

10.1093/neuonc/noaf201.1513 Get It

Abstract BACKGROUND Despite multimodal treatment, brain tumors frequently recur and are often life-threatening. Patients commonly experience progressive neurologic decline, significantly impacting quality of life. We aimed to characterize the symptom burden of central nervous system tumors and to explore patient and caregiver experiences. METHODS In this observational study (NCT06676306), we conducted semi-structured interviews with 22 patients receiving care through the Mayo Clinic Neuro-oncology division. Caregivers were invited to participate. Demographic data were obtained from electronic medical records. Interviews were recorded, transcribed, and analyzed thematically. RESULTS Twenty-two patients (9/22, 41% female; median age 41.5 years, range 24–71) and 13 caregivers (13/22, 59%) participated. Diagnoses included astrocytoma, IDH mutant (8/22, 36%), glioblastoma (4/22, 18%), oligodendroglioma (3/22, 14%), astrocytoma, IDH wildtype (2/22, 9%), and other (5/22, 23%). The most frequently reported symptoms were headaches (13/22, 59%), cognitive changes (8/22, 36%), and fatigue (7/22, 32%). Among twenty patients who discussed treatment impacts, the most common were fatigue (45%), cognitive changes (40%), and mood changes (40%). Caregivers reported emotional toll (13/13, 100%), career changes (7/13, 54%), and difficulty balancing responsibilities (6/13, 46%). Twenty-one patients shared coping strategies, including faith (29%), hobbies (24%), and exercise (19%). All 20 respondents who discussed overall experience with neuro-oncology care reported a positive overall experience (100%), with the patient–neuro-oncologist relationship (40%) and communication (39%) cited as key contributors. For 19 patients who discussed treatment outcomes, quality of life (26%), maintaining function (21%), and tumor stability (21%) were paramount. For 9 caregivers who discussed treatment outcomes, 44% prioritized quality of life and 44% reported desire for a cure. CONCLUSIONS Brain tumors and their treatments affect patients and caregivers across physical, emotional, and social domains. Strong relationships and communication with the care team are central to patient satisfaction. Quality of life should be prioritized in neuro-oncology research and trials.
CTNI-08. WSD0922-FU THERAPY IN PATIENTS WITH EGFR MUTANT GLIOBLASTOMA – UPDATES FROM THE DOSE EXPANSION COHORTS OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)
Kizilbash, Sani H. , Jaeckle, Kurt A. , Mrugala, Maciej , Allred, Jacob B., Steinert, Kimberly O., Reid, Joel R., Lammers, Anita, Erdmann, Abby, Casini, Angela , Venegas, S Sáchez-Gey, Woolard, Theresa McCabe, Moriarty, Cheryl, Zhong, Wei , Uhm, Joon H. , Campian, Jian , Ruff, Michael W. , Neth, Bryan J. , Caron, Samantha, Rosenfeld, Steven S. , Porter, Alyx B. , Adjei, Alex A. , Neth, Byran J. , Kizilbash, Sani H , Sherman, Wendy , Safgren, Stephanie L. , Erdmann, Abby, He, Lihong , Venegas, Selena, Zhong, Wei, Maqbool, Muhammad Asad , Sener, Uğur , Galanis, Evanthia , Ensign, Shannon P. Fortin , Burns, Terry C. , Parney, Ian F. , Raghunathan, Aditya , Vaubel, Rachael A. , Giannini, Caterina , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v126-v126

10.1093/neuonc/noaf201.0505 Get It

Abstract WSD0922-Fu is an oral, CNS-penetrant, small molecule EGFR inhibitor which potently inhibits EGFR aberrations specific to non-small cell lung cancer (NSCLC) and glioblastoma (GBM). MC1914 (NCT04197934) is a first-in-human phase 1 trial in patients with EGFR aberrant recurrent GBM and NSCLC. After determining the maximum tolerated dose, adults with recurrent GBM were treated in two expansion cohorts: (a) non-surgical cohort (6/12 patients thus far): EGFRvIII mutation, first recurrence; food-effect study included (b) surgical cohort (6/6 patients), any EGFR mutation, any recurrence; window-of-opportunity study (WOO) included. Among these 12 patients, median age = 60 years; 50% female; 58% ECOG 0). All patients received prior radiation and temozolomide. After the WOO or food-effect study, patients were dosed at 120 mg BID (5 days on, 2 days off), and escalated to 160 mg BID (5 days on, 2 days off) based on tolerability. Common adverse events (&gt;40%) are comparable to other EGFR inhibitors (acneiform rash, diarrhea, fatigue, xerosis, pruritis). Treatment-related grade 3+ adverse events were limited to lymphopenia (n = 1). WSD0922-Fu exposure in the fed state exceeded the fasted state (median plasma Cmax and AUC0-24h are 1.6x and 1.3x, respectively) with a delayed Tmax (6.0 vs 1.8 hours). For the WOO, time between last dose administered to tumor collection ranged between 4 - 13.5 hours. Median tumor WSD0922-Fu concentration was 0.76 µg/g; estimated median unbound tumor concentration was 24.9 ng/g and within expectations for pharmacodynamic effect. Median brain/plasma ratio = 0.59; median unbound brain/unbound plasma = 0.88. Enrollment to the non-surgical cohort is ongoing, so formal efficacy data remain immature. However, examples of clinical efficacy will be shown along with data on recurrence patterns. Phase 2 clinical trial development is in progress.
INNV-52. Mixed histiocytosis of the thoracic dura: a rare presentation of Mixed Erdheim-Chester Disease and Rosai-Dorfman Disease mimicking IgG4-Related Disease
Abeykoon, Jithma P. , Steel, Stephanie J., McKeon, Andrew, White, Jessica B. , Go, Ronald S. , Rech, Karen L. , Tobin, W. Oliver , McKeon, Andrew, Banks, Samantha A.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v237-v237

10.1093/neuonc/noaf201.0941 Get It

Abstract BACKGROUND Mixed histiocytic neoplasms with overlapping features of Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD) are extremely rare and diagnosis may be delayed due to lack of awareness and complex histology features. METHODS We report a case of mixed ECD/RDD misdiagnosed as IgG4-related disease and review the literature. RESULTS A 50-year-old man presented for evaluation of spastic paraparesis in the context of a thoracic dural lesion. Two years prior he developed an inflammatory monoarthritis concerning for rheumatoid arthritis unresponsive to methotrexate. Six months prior he developed leg spasms, gait spasticity, and urinary incontinence. MRI demonstrated a T2 hypointense enhancing epidural mass with spinal cord compression. Epidural biopsy showed fibrosis and non-specific inflammation. Given elevated serum IgG4 (170 mg/dL) and clinical findings, he was diagnosed with IgG4-related disease. He received high dose prednisone and etanercept without radiographic or clinical improvement. He then presented to our institution. Given high concern for RDD, he underwent FDG-PET CT which demonstrated an infiltrative process and FDG avid regions in the upper thoracic spinal cord, paranasal sinus, renal hilum, perivascular abdominal vessels, testicle, and multiple joint effusions. Biopsy of left testicle demonstrated CD163-positive histiocytes which coexpressed S100, cyclin D1, and OCT2, consistent with RDD. Biopsy of the left shoulder synovium demonstrated an atypical CD163-positive histiocytic infiltrate expressing Factor XIIIa, cyclin D1 and S100 (partial), and appeared negative for OCT2, consistent with ECD. The atypical histiocytes in both biopsies were negative for CD1a and BRAF V600E by immunohistochemistry. Genomic sequencing of the testicular tissue demonstrated a MAP2K1 (Q56P) alteration. He was treated with radiation therapy targeting the dural lesion with temporarily worsening symptoms improved with steroids and started on cobimetinib. DISCUSSION This case expands on the phenotypic description of mixed ECD/RDD. Histiocytic neoplasms should be considered in the differential diagnosis of dural based lesions.
BIOM-66. MODERN MOLECULAR PROFILING RECONTEXTUALIZES THE RTOG-0539 TRIAL AND REVEALS HIDDEN HIGH-RISK AND RADIOTHERAPY RESISTANT MENINGIOMAS
Yefet, Leo, Landry, Alex, Wang, Justin Z. , Patil, Vikas , Gui, Chloe , Ajisebutu, Andrew, Pugh, Stephanie, Nassiri, Farshad , Aldape, Kenneth, Zadeh, Gelareh, Yefet, Leo, Landry, Alexander , Liu, Jeff , Ellenbogen, Yosef

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v39-v39

10.1093/neuonc/noaf201.0154 Get It

Abstract Meningiomas are the most common primary intracranial tumors and exhibit clinical heterogeneity. Radiotherapy (RT) remains the only adjuvant therapy, but response is variable and biomarkers are limited. RTOG-0539 is the first prospective phase 2 trial to stratify meningioma patients for adjuvant RT based on clinical risk. Here, we apply modern molecular tools to this cohort and uncover correlates of RT response. To do so, tumor tissue from 100 RTOG-0539 patients was profiled using DNA methylation arrays, RNA sequencing, and whole-exome sequencing. Recurrence scores, Molecular Groups, gene expression, and copy number alterations were compared across clinical groups and between RT responders and non-responders. Using this approach, modern grading criteria, including brain invasion, TERT mutation, CDKN2A/B deletion and 1p/1q status, would reclassify 10% of tumors and alter treatment group assignment in 7%. Notably, non-responders to RT had more frequent 1p and 14q loss, and greater copy number burden. In addition, transcriptomic and epigenetic profiling revealed immune-related signatures in RT responders and upregulation of cell cycle–related pathways in RT non-responders, several of which overlapped with targets of vorinostat, a histone deacetylase inhibitor validated in aggressive meningioma models. Of particular importance, the Proliferative Molecular Group was an independent predictor of post-RT recurrence in multivariable analysis, outperforming WHO grade. In conclusion, multi-omic analysis of the RTOG-0539 cohort shows that updated WHO grading criteria, incorporating molecular and cytogenetic features, improve risk stratification. However, molecular classification, particularly the Proliferative group, remains an independent and stronger predictor of RT response. These findings support integrating molecular biomarkers alongside modern grading frameworks to guide treatment and trial design in meningioma.